EP0030861A2 — Isoquinoline acetic acids and pharmaceutical compositions thereof
Assigned to Pfizer Inc · Expires 1981-06-24 · 45y expired
What this patent protects
Novel isoquinoline acetic acids and derivatives thereof oftheformulae and wherein R is hydrogen or alkyl or 1 to 3 carbon atoms, R 1 is-CH 2 -X or-O-CH 2 -X, R 2 is-CH 2 -X, R, is-X or-CH 2 -X, and R 4 is hydrogen or methyl, wherein X is phenyl or monosubstit…
USPTO Abstract
Novel isoquinoline acetic acids and derivatives thereof oftheformulae and wherein R is hydrogen or alkyl or 1 to 3 carbon atoms, R 1 is-CH 2 -X or-O-CH 2 -X, R 2 is-CH 2 -X, R, is-X or-CH 2 -X, and R 4 is hydrogen or methyl, wherein X is phenyl or monosubstituted or disubstituted phenyl, said substituents being chloro, bromo or fluoro; are useful as aldose reductase inhibitors and as therapeutic agents for the treatment of chronic diabetic complications, especially diabetic cataracts. Also disclosed are pharmaceutical compositions containing the novel compounds of this invention and a method of treatment of diabetic cataracts by administration of effective amounts of the novel compounds described herein.
Drugs covered by this patent
- Lynparza (olaparib) · AstraZeneca
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.